Equities Analysts Offer Predictions for TENX Q1 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Tenax Therapeutics in a research report issued to clients and investors on Wednesday, March 26th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will post earnings of ($1.06) per share for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($3.52) EPS, Q4 2025 earnings at ($4.73) EPS, FY2025 earnings at ($10.46) EPS, FY2026 earnings at ($5.76) EPS, FY2027 earnings at ($4.86) EPS, FY2028 earnings at ($3.08) EPS and FY2029 earnings at ($1.03) EPS.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.34.

Several other brokerages also recently weighed in on TENX. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a research note on Monday, March 10th. Finally, StockNews.com assumed coverage on Tenax Therapeutics in a research note on Saturday. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Tenax Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Tenax Therapeutics Stock Performance

Shares of Tenax Therapeutics stock opened at $6.49 on Monday. Tenax Therapeutics has a one year low of $2.77 and a one year high of $7.89. The company has a market capitalization of $25.73 million, a PE ratio of -1.22 and a beta of 2.20. The company has a 50-day simple moving average of $6.43 and a two-hundred day simple moving average of $5.44.

Institutional Investors Weigh In On Tenax Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TENX. Two Sigma Investments LP purchased a new position in Tenax Therapeutics in the 4th quarter worth $84,000. Sphera Funds Management LTD. acquired a new position in shares of Tenax Therapeutics in the third quarter valued at about $101,000. Geode Capital Management LLC raised its stake in shares of Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Tenax Therapeutics during the fourth quarter worth about $166,000. Finally, Janus Henderson Group PLC purchased a new stake in Tenax Therapeutics in the fourth quarter valued at approximately $1,026,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.